Fatal thrombotic event after infusion of recombinant activated factor VII after cardiac surgery  by Pichon, N. et al.
Brief CommunicationsFatal thrombotic event after infusion of recombinant activated factor VII
after cardiac surgery
N. Pichon, MD,a,b F. Bellec, MD,a S. Sekkal, MD,c J. P. Marsaud, MD,d,e M. Laskar, MD, PhD,c,e B. FranÅois, MD,a,b
and P. Vignon, MD, PhD,a,b,e Limoges, FranceH
emorrhagic shock is a major complication of cardiotho-
racic surgery that occurs when standard surgical and
medical hemostatic procedures fail to stop hemorrhage.
Recombinant activated factor VII (rFVIIa; NovoSeven,
Novo Nordisk, Denmark) is a prohemostatic agent increasingly used
as rescue therapy in cardiothoracic surgery, but its safety in this in-
dication remains to be investigated. We report a fatal thrombotic
event that occurred within 48 hours after the administration of
rFVIIa for a refractory hemorrhagic shock after cardiothoracic
surgery.
Clinical Summary
A 57-year-old hypertensive male patient underwent an aortic valve
and ascending aorta replacement (Carbo-Seal Valsalva Ascending
Aortic Prosthesis CP-023; CarboMedics, Austin, Texas) for a type
A aortic dissection including both carotid arteries without antegrade
carotid perfusion (Figure 1). Postoperatively, the patient had severe
hemorrhagic shock resulting from active bleeding from the chest
tubes (10 mL $ kg21 $ h21), despite the transfusion of 2700 mL
of blood from a cell salvage machine, 9 units of packed red blood
cells (PRBC), 12 units of fresh-frozen plasma (FFP), 2 units of
pooled platelet concentrates, 2 g of fibrinogen, and calcium chloride.
The patient had a metabolic acidosis (pH 7.24, base–deficit 8.7 mEq
$ L21, and lactates 9.11 mmol $ L21), a coagulopathy (international
normalized ratio (INR) 3.38, platelet count 593 109.L-1, fibrinogen
0.79 g $ L21, activated partial thromboplastin time [APTT] 75.5 s),
and anemia (71 g $ L21). Owing to persistent bleeding exteriorized
by chest tubes (.500 mL $ h21), the patient was again operated on
at H13. A source of bleeding was disclosed and surgically repaired.
Active bleeding through chest tubes persisted and led to a second
surgical re-exploration under cardiopulmonary bypass, which failed
to reveal any surgical source of bleeding. Refractory hemorrhagic
shock (lactates 13.86 mmol $ L21, hemoglobin 59 g $ L21) owing
to sustained bleeding from chest tubes (15 mL $ kg21 $ h21) and se-
vere coagulopathy (INR 1.74, platelet count 653 109 $ L21, APTT
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blood products (24 units of PRBC, 30 units of FFP, 5 units of
pooled platelet concentrates, and 6 g of fibrinogen). The correct bi-
lateral carotid perfusion was confirmed by transcranial Doppler
monitoring during surgery. A transesophageal echocardiogram
ruled out a cardiac source of emboli and excluded a compressive
atrial hematoma. The administration of rFVIIa was discussed by
cardiac surgeons, anesthesiologists, and intensivists. The empirical
dosing scheme was an intravenous bolus injection of 8.4 mg (90
mg/kg) on the basis of published reports. After this single dose of
rFVIIa, the bleeding from chest tubes decreased below 1 mL $
kg21 $ h21 and the coagulopathy dramatically improved. No fur-
ther second dose was administered. Our patient had no recurrence
of bleeding and presented an adapted awakening without sedation
within 24 hours. Unfortunately, 48 hours after the procoagulant in-
jection, the patient exhibited a bilateral mydriasis with associated
signs consistent with brain death. The computed tomographic ce-
rebral scan confirmed an extended stroke resulting from a bilateral
thrombosis of carotid arteries (Figure 2). The spouse declined the
autopsy.
Discussion
Excessive postoperative bleeding is a common complication after
cardiothoracic surgery with an incidence of 11%.1 Massive hemor-
rhage requiring surgical reinterventions occurs in about 6% of sur-
gically treated patients.1,2 rFVIIa is increasingly used with success
to control refractory hemorrhage in patients undergoing complex
cardiothoracic surgery.1 The estimated number of hospitalized pa-
tients treated with rFVIIa in the United States increased from 349
in 2000 (the first full year after licensure) to 4520 in 2004.3 The sin-
gle dose of rFVIIa administered to cardiothoracic surgical patients
ranged from 11.1 to 180 mg/kg and 75% of adult patients received
a total dose 90 mg/kg or less.1
There is no apparent thrombotic event after injection of rFVIIa
in most reports and studies.1,4 Nevertheless, the safety of rFVIIa
cannot be extrapolated from sporadic reports and accumulated ex-
perience remains limited. In a cumulated experience combining
thromboembolic complications in patients who received rFVIIa
for a refractory hemorrhage, an incidence of 5.3% was reported
and was similar to that reported from 13 Novo Nordisk–sponsored
clinical trials regarding the use of rFVIIa in settings other than
cardiac surgery.1 A word of caution emanating from the US
Food and Drug Administration suggested an increase in thrombo-
embolic events in patients treated with rFVIIa for unlabeled con-
ditions.3
It has been postulated that bleeding after cardiac surgery is fre-
quently related to disseminated intravascular coagulation and that
activating the hemostatic system with rFVIIa in this setting may
increase the risk of thromboembolic events.5 Confounding factors
to establish the relationship between rFVIIa administration andy 2008
Brief CommunicationsFigure 2. Bilateral ischemic stroke on
CT cerebral scan.
Figure 1. Transverse computed tomo-
graphic scan showing a type A aortic
dissection (A) with a bilateral carotid
dissections (B: arrows).reported thromboembolic events include up-regulation of tissue
factor expression after cardiopulmonary bypass, which facilitates
clot formation, concomitant medications, and pre-existing medical
conditions.3,4 In our patient, the bilateral dissection of carotid
arteries and the two cardiopulmonary bypass procedures were pre-
sumably major predisposing factors for stroke. Therefore, it seems
difficult to assert that fatal stroke is only secondary to rFVIIa
administration.
In conclusion, we report herein the first case of a bilateral throm-
bosis of carotid arteries leading to brain death after a single admin-
istration of rFVIIa in a patient who underwent complicated surgical
repair of a type A aortic dissection extended to both carotid arteries.
Although efficient as a rescue therapy in patients with hemorrhagic
shock after cardiothoracic surgery, rFVIIa may be associated with
an increased risk of stroke in this setting. Randomized controlled
trials are needed to establish its safety.The Journal of ThoReferences
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